US2025177290A1PendingUtilityA1

Drug-eluting surgical articles and methods of use thereof

60
Assignee: BIOSAPIEN INCPriority: May 13, 2022Filed: Nov 12, 2024Published: Jun 5, 2025
Est. expiryMay 13, 2042(~15.8 yrs left)· nominal 20-yr term from priority
Inventors:Khatija Pinky Ali
A61K 31/513A61K 9/4816A61K 9/4808A61P 35/00A61L 2300/416B33Y 80/00A61L 31/16A61K 9/0024A61L 31/146
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein is a biomaterial and a method of use thereof for treating a condition. A biomaterial of the disclosure can be, for example, a surgical article. Implantation of a biomaterial disclosed herein into a subject can treat, for example, cancer.

Claims

exact text as granted — not AI-modified
1 . A biomaterial comprising a plurality of geometric elements and a therapeutic agent, wherein:
 (a) a first geometric element of the plurality of geometric elements comprises a first polymer and the therapeutic agent, wherein at least a portion of the first geometric element is porous;   (b) a second geometric element of the plurality of geometric elements comprises a second polymer, wherein at least a portion of the second geometric element is substantially non-porous;   (c) the at least the portion of the first geometric element is adjacent to the at least the portion of the second geometric element; and   (d) the first polymer or the second polymer has a number average molar mass of greater than 6,000 Dalton (Da).   
     
     
         2 . The biomaterial of  claim 1 , wherein the first polymer and the second polymer have a number average molar mass of greater than 6,000 Da. 
     
     
         3 . The biomaterial of  claim 1 , wherein the number average molar mass of the first polymer and the number average molar mass of the second polymer are different. 
     
     
         4 - 6 . (canceled) 
     
     
         7 . The biomaterial of  claim 1 , wherein the number average molar mass of the first polymer is at least about 10 kDa. 
     
     
         8 . The biomaterial of  claim 1 , wherein the number average molar mass of the first polymer is at most about 100 kDa. 
     
     
         9 . (canceled) 
     
     
         10 . The biomaterial of  claim 1 , wherein the number average molar mass of the second polymer is at least about 10 kDa. 
     
     
         11 . The biomaterial of  claim 1 , wherein the number average molar mass of the second polymer is at most about 100 kDa. 
     
     
         12 . The biomaterial of  claim 1 , wherein the first polymer comprises polycaprolactone (PCL), poly lactic acid (PLA), poly L-lactide-glycolic acid (PLGA), or polyethylene glycol diacrylate (PEGDA). 
     
     
         13 . The biomaterial of  claim 1 , wherein the first polymer comprises PCL. 
     
     
         14 . The biomaterial of  claim 1 , wherein the second polymer comprises polycaprolactone (PCL), poly lactic acid (PLA), poly L-lactide-glycolic acid (PLGA), or polyethylene glycol diacrylate (PEGDA). 
     
     
         15 . The biomaterial of  claim 1 , wherein the second polymer comprises PCL. 
     
     
         16 . The biomaterial of  claim 1 , wherein the therapeutic agent comprises an anti-cancer agent. 
     
     
         17 . The biomaterial of  claim 1 , wherein the therapeutic agent comprises an antimicrobial agent, an antibiotic, a local anesthetic or analgesic, a statin, and/or an anti-inflammatory agent. 
     
     
         18 . The biomaterial of  claim 1 , wherein the therapeutic agent comprises capecitabine, cisplatin, carboplatin, cyclophosphamide, docetaxel, doxorubicin, etoposide, fluorouracil, floxuridine, gemcitabine, ifosfamide, irinotecan, methotrexate, oxaliplatin, paclitaxel, pemetrexed, raltitrexed, regorafenib, vincristine, or vinorelbine. 
     
     
         19 . The biomaterial of  claim 1 , wherein the therapeutic agent comprises fluorouracil. 
     
     
         20 . The biomaterial of  claim 1 , wherein an amount of the therapeutic agent in the first geometric element is greater than 30% by weight of the first polymer. 
     
     
         21 . (canceled) 
     
     
         22 . The biomaterial of  claim 20 , wherein the amount of the therapeutic agent in the first geometric element is greater than 35% by weight of the first polymer. 
     
     
         23 . The biomaterial of  claim 20 , wherein the amount of the therapeutic agent in the first geometric element is greater than 5% by weight of a combination of the first polymer and the second polymer. 
     
     
         24 . (canceled) 
     
     
         25 . The biomaterial of  claim 20 , wherein the amount of the therapeutic agent in the first geometric element is greater than 35% by weight of the combination of the first polymer and the second polymer. 
     
     
         26 - 33 . (canceled) 
     
     
         34 . The biomaterial of  claim 20 , wherein the porosity of first geometric element is at least about 10% as ascertained by scanning electron microscopy, thermoporometry and/or cryoporometry. 
     
     
         35 - 90 . (canceled)

Join the waitlist — get patent alerts

Track US2025177290A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.